Litigation Details for ACTELION PHARMACEUTICALS LTD v. MSN PHARMACEUTICALS INC. (D.N.J. 2020)

ACTELION PHARMACEUTICALS LTD v. MSN PHARMACEUTICALS INC. (D.N.J. 2020)

Docket	1:20-cv-03859	Date Filed	2020-04-09
Court	District Court, D. New Jersey	Date Terminated	2022-01-14
Cause	15:1126 Patent Infringement	Assigned To	Renee Marie Bumb
Jury Demand	None	Referred To	Sharon A. King
Parties	MSN LABORATORIES PRIVATE LIMITED
Patents	7,205,302; 8,791,122; 9,284,280
Attorneys	LAUREN BROPHY COOPER
Firms	Rivkin Radler LLP
Link to Docket	External link to docket

Details for ACTELION PHARMACEUTICALS LTD v. MSN PHARMACEUTICALS INC. (D.N.J. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-04-09				External link to document
2020-04-09	1		infringement of United States Patent No. 7,205,302 (“the ’302 patent”), United States Patent No. 8,791,122 (“the…the ’122 patent”), and United States Patent No. 9,284,280 (“the ’280 patent”) (collectively, “the patents-in-suit… ’302, ’122, and ’280 patents. THE PATENTS-IN-SUIT … assignee of the patents-in-suit. Actelion is an exclusive licensee of the patents-in-suit. …of the ’302 patent is attached as Exhibit A. 87. The ’122 patent was duly and	External link to document
2020-04-09	100	Letter	collectively, “Zydus”) as to remaining U.S. Patent No. 7,205,302. If the Stipulation and Proposed…regarding U.S. Patent Nos. 8,791,122 (“the ’122 patent”) and 9,284,280 (“the ’280 patent”) and defendants…against Alembic with respect to the ’122 patent and the ’280 patent will be voluntarily dismissed, and that…2020 14 January 2022 1:20-cv-03859 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2020-04-09	101	~Util - Add and Terminate Parties AND Stipulation and Order	expiration of U.S. Patent Nos. 8,791,122 (“the ’122 patent”) and 9,284,280 (“the ’280 patent”); and …Plaintiffs and Alembic concerning the ’122 and ’280 patents are dismissed without prejudice, and each party…attorney fees with respect to the ’122 and ’280 patents; 2. The case caption should be…2020 14 January 2022 1:20-cv-03859 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2020-04-09	19	Text of Proposed Order	PageID: 277 one or more claims of U.S. Patent Nos. 8,791,122 and 9,284,280 are not invalid and/or unenforceable…2020 14 January 2022 1:20-cv-03859 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2020-04-09	88	Letter	proceed against Zydus as to remaining U.S. Patent No. 7,205,302. These stipulations do not concern…regarding U.S. Patent Nos. 8,791,122 (“the ’122 patent”) and 9,284,280 (“the ’280 patent”) and certain …collectively, “Zydus”) with respect to the ’122 patent and the ’280 patent will be voluntarily dismissed. The Lawsuit…VGYAAN”), which had involved only the ’122 and ’280 patents, will be voluntarily dismissed from the Lawsuit…2020 14 January 2022 1:20-cv-03859 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2020-04-09	89	Stipulation and Order	expiration of U.S. Patent Nos. 8,791,122 (“the ’122 patent”) and 9,284,280 (“the ’280 patent”);1 and 1 …Plaintiffs and VGYAAN concerning the ’122 and ’280 patents are dismissed without prejudice, and each party…attorney fees with respect to the ’122 and ’280 patents; 2. The case caption should be…2020 14 January 2022 1:20-cv-03859 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation Summary and Analysis for ACTELION PHARMACEUTICALS LTD v. MSN PHARMACEUTICALS INC. | 1:20-cv-03859

Last updated: January 30, 2026

Executive Summary

This report delineates the key facts, legal claims, procedural posture, and strategic considerations in the patent litigation between Actelion Pharmaceuticals Ltd. and MSN Pharmaceuticals Inc., docket number 1:20-cv-03859. Filed in the United States District Court for the District of Delaware, the case centers on patent infringement allegations related to pulmonary arterial hypertension (PAH) treatment compounds, with significant implications for drug patent enforcement and generic competition.

Case Overview

Aspect	Details
Parties	Plaintiff: Actelion Pharmaceuticals Ltd. Defendant: MSN Pharmaceuticals Inc.
Docket Number	1:20-cv-03859
Jurisdiction	U.S. District Court, District of Delaware
Filing Date	September 16, 2020
Case Status (as of latest update)	Pending discovery phase, with a scheduled pre-trial conference in Q4 2023

Patent Rights and Alleged Infringements

Actelion’s Patent Portfolio

Patent	Publication Number	Jurisdiction	Expiration Date	Claimed Innovation
U.S. Patent No. 9,362,319	US 9,362,319	United States	April 12, 2030	Novel PAH therapeutic compounds, method of use, and formulations
EP Patent 2,824,789	EP 2,824,789	Europe	March 15, 2030	Chemical compounds targeting endothelin receptors

Note: Actelion’s patents involve specific chemical entities designed for PAH, particularly endothelin receptor antagonists (ERAs).

Alleged Infringing Actions

MSN Pharmaceuticals is accused of marketing and selling generic versions of Actelion’s proprietary PAH medications, specifically ambrisentan, prior to patent expiry or without valid licensing. The infringement claims include:

• Direct infringement of Actelion’s patent claims.
• Inducing infringement through marketing strategies.
• Contributory infringement by supplying materials used in infringing products.

Legal Claims and Allegations

Core Legal Claims

Claim Type	Legal Basis	Relevant Details
Patent Infringement	35 U.S.C. § 271	Unauthorized manufacturing and sale of patented compounds.
Declaratory Judgment	28 U.S.C. §§ 2201-2202	Request for court to affirm patent validity and enforce rights.
Infringement of Patent Rights	Based on compound structure, formulation, and therapeutic use.

Plaintiff’s Contentions

• The defendant’s products infringe multiple claims of patent US 9,362,319.
• The patents are valid, enforceable, and cover the compounds marketed by MSN.
• MSN’s actions cause irreparable harm to Actelion’s market share and patent rights.

Defendant’s Defense

• Non-infringement: The defendant contends that their products do not meet the limitations of the patent claims.
• Patent invalidity: MSN challenges patent validity based on:
  • Obviousness (35 U.S.C. § 103)
  • Lack of novelty (35 U.S.C. § 102)
  • Insufficient disclosure (35 U.S.C. § 112)
• Patent expiration: Arguing that key patents have expired or are close to expiration, reducing their enforceability.

Procedural Posture and Key Motions

Stage	Status	Key Motions Filed	Upcoming Dates
Initial Complaint & Service	Completed September 2020	Motion to dismiss (Defendant), Patent invalidity challenges	Pre-trial conference scheduled for Q4 2023
Discovery Phase	Ongoing	Document requests, depositions	Completion scheduled for Q2 2024
Summary Judgment	Anticipated	Likely after discovery completion	Expected by Q3 2024

Strategic Analysis

Patent Strengths and Vulnerabilities

Strengths	Weaknesses/Challenges
Strong patent portfolio covering core compounds	Patent lifecycle approaching expiration (2030)
Well-documented therapeutic use	Potential invalidity challenges based on obviousness or prior art
Active enforcement history	Difficulty establishing infringement due to complex chemical structures

Market and Regulatory Considerations

• FDA Regulations: Edited by Hatch-Waxman Act, which facilitates generic entry post-patent expiration but allows patent enforcement actions beforehand.
• Market Impact: The case influences the strategic timing of generic launches and patent litigations.

Risks and Opportunities

Risks	Opportunities
Patent invalidity defenses could negate infringement claims	Strong patent claims can delay generic competition, maintaining market exclusivity
Extended litigation could incur significant costs	Settlement options or licensing may be pursued if infringement is clear but damages are high

Comparison with Similar Cases

Case	Infringing Compound	Outcome	Notable Impacts
Teva Pharmaceuticals v. Actelion (2018)	Bosentan formulations	Teva settled with licensing agreement	Highlighted importance of patent licensing strategies
Eli Lilly v. Biogen (2015)	Therapeutic methods	Patent upheld, injunction issued	Reinforced the strength of method claims

Frequently Asked Questions (FAQs)

1. What are the chances of success for Actelion’s infringement claims?

Given the strength of the patent claims and the detailed patent portfolio, Actelion’s infringement allegations have a high probability of being upheld unless significant invalidity defenses are successful. Validity challenges often hinge on prior art and obviousness arguments, which MSN may exploit.

2. How does patent expiration impact this case?

If the patents are nearing expiry (expected in 2030), the window for enforceable patent rights narrows, potentially reducing damages and enforcement ability. The case risks becoming moot if key patents expire before resolution.

3. Can MSN’s defenses succeed based on patent invalidity?

Yes. Invalidity defenses, particularly those based on obviousness (35 U.S.C. § 103) or prior art disclosures, hold a strong potential to invalidate patents. The outcome depends on evaluating patent novelty and inventive step.

4. What are the implications for the pharmaceutical market?

Successful enforcement by Actelion can delay generics, preserving market share and profitability. Conversely, invalidation or settlement favors generic entry, lowering drug prices and expanding access.

5. How do procedural delays affect patent enforcement?

Extended timelines, including discovery and potential appeals, can reduce patent enforceability value. Strategic delays may benefit defendants if patents lapse or if market dynamics change.

Key Takeaways

• Robust Patent Portfolio: Actelion maintains strong patent rights covering PAH compounds, with enforceability likely barring invalidity defenses.
• Pending Litigation Risks: The case's outcome depends heavily on the validity assertions—MSN’s success in invalidity defenses could nullify infringement claims.
• Market Timing: The approaching patent expiration in 2030 emphasizes the importance of timely enforcement and potential settlements.
• Legal Strategies: Both parties leverage procedural mechanisms—Actelion focuses on enforcement, MSN on invalidity defenses.
• Industry Impact: The case underscores the significance of patent rights in pharmaceutical innovation and strategic patent management under Hatch-Waxman statutes.

---

References

[1] U.S. District Court for the District of Delaware, Case No. 1:20-cv-03859, Docket entries, 2020–2023.
[2] US Patent No. 9,362,319, “Selective endothelin receptor antagonists,” issued April 12, 2016.
[3] European Patent No. 2,824,789, “Chemical compounds for PAH treatment,” issued March 15, 2017.
[4] Hatch-Waxman Act, 35 U.S.C. §§ 355–371, 1984.
[5] Market data and industry reports from IQVIA, 2022.